Clinical trial Recruiting at 1 site Observational Ages 18 and up

National registry of rapid unexplained coronary in‑stent restenosis (RECUR)

Official title: National Multicenter Cohort Registry Study of Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

Run by China National Center for Cardiovascular Diseases · NCT05437965 · Data updated 2026-11-12

This nationwide registry will collect clinical and test data to see if patterns or biomarkers link to rapid unexplained in‑stent restenosis in adults with coronary stents.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorChina National Center for Cardiovascular Diseases
Government
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedJune 3, 2020
Main results expectedApril 1, 2035
Study endsApril 1, 2035
Registry record updatedAugust 8, 2025
Trial IDNCT05437965 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older who meet diagnostic criteria for RECUR, can provide informed consent, and are able to attend follow‑up at participating centers are ideal candidates.

Probably not a fit

Patients with known autoimmune or rheumatic vasculitis, variant angina, coronary dissection, thrombophilia, stent underexpansion, severe comorbidities limiting life expectancy <12 months, psychiatric disorders, or inability to complete follow‑up are unlikely to benefit from inclusion.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a national, multicenter observational cohort registry enrolling adults with rapid recurrences of unexplained coronary in‑stent restenosis (RECUR). Participating centers will collect standardized clinical data, imaging, laboratory biomarkers, treatment details, and follow‑up outcomes while patients receive usual care from experienced clinicians. The project aims to build a diagnostic assessment framework and enable longitudinal analyses to identify patterns, risk factors, and potential biomarkers associated with rapid unexplained restenosis. Data will be centrally managed and analyzed to inform diagnostic criteria and guide future interventional research.

Why it matters

Potential benefit: If successful, the registry could help identify causes or biomarkers of rapid in‑stent restenosis and improve diagnosis and treatment strategies to reduce repeat events.

How similar studies have gone: Previous multicenter registries and biomarker studies of in‑stent restenosis have identified risk factors and inflammatory markers, but focused registries on rapid unexplained recurrences are relatively novel and less well studied.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Age ≥ 18 years;
2. Patients meeting the diagnostic criteria for Rapid rEcurrences of Coronary Unexplained in-stent Restenosis (RECUR);
3. Patients fully informed about the trial procedures who provide written informed consent.

Exclusion Criteria:

1. Patients presenting with any of the following:

   * Other severe comorbidities (e.g., malignant tumors, heart failure) with a life expectancy \<12 months;

     * Known autoimmune/rheumatic diseases including systemic lupus erythematosus, Takayasu arteritis, Behçet's disease, polyarteritis nodosa, Wegener granulomatosis (granulomatosis with polyangiitis), eosinophilic arteritis, giant cell arteritis, rheumatoid arthritis, or IgG4-related disease;

       * Variant angina (Prinzmetal's angina);

         * Coronary artery dissection;

           * Thrombophilia;

             * Stent underexpansion.
2. Presence of psychiatric disorders;
3. Known inability to complete expected study follow-up for any reason;
4. Patients deemed ineligible for enrollment by the investigator.

Where it's running

  • Jia Lei
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.